title: Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
abstract: The Breast Cancer Disease Site Group of Cancer Care Ontario identified the need for new guidelines for the adjuvant systemic therapy of early-stage breast cancer. The specific question to be addressed was "What is the optimal adjuvant systemic therapy for female patients with early-stage operable breast cancer, when patient and disease factors are considered?" A systematic review was prepared based on literature searches conducted using the medline and embase databases for the period January 2008 to March 5, 2012, and updated to May 12, 2014. Guidelines were located from that search, from the Standards and Guidelines Evidence directory of cancer guidelines, and from the Web sites of major guideline organizations. The literature located was subdivided into the broad categories of chemotherapy, hormonal therapy, and therapy targeted to her2 (human epidermal growth factor receptor 2). Although several of the systemic therapies discussed in this guideline can be considered in the neoadjuvant setting, the review focused on trials with rates of disease-free and overall survival as endpoints and thus excluded several trials that used pathologic complete response as a primary endpoint. Based on the systematic review, the working group drafted recommendations on the use of chemotherapy, hormonal therapy, and targeted therapy; based on their professional experience, they also drafted recommendations on patient and disease characteristics and recurrence risk. The literature review and draft recommendations were circulated to a consensus panel of medical oncologists who had expertise in breast cancer and who represented the regions of Ontario. Items without initial consensus were discussed at an in-person consensus meeting held in Toronto, November 23, 2012. The final recommendations are those for which consensus was reached before or at the meeting. Some of the key evidence was revised after the updated literature search. Evidence reviews for systemic chemotherapy, endocrine therapy, and targeted therapy for her2-positive disease are reported in separate articles in this supplement. The full three-part 1-21 evidence-based series, including complete details of the development and consensus processes, can be found on the Cancer Care Ontario Web site at https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/breast-ebs.
authors.affiliation: Sunnybrook Health Science Centre, Toronto, ON.
authors.forename: A
authors.initials: A
authors.lastname: Eisen
authors.affiliation: Program in Evidence-Based Care, Cancer Care Ontario; and Department of Oncology, McMaster University, Hamilton, ON.
authors.forename: G G
authors.initials: GG
authors.lastname: Fletcher
authors.affiliation: Sunnybrook Health Science Centre, Toronto, ON.
authors.forename: S
authors.initials: S
authors.lastname: Gandhi
authors.affiliation: Cancer Centre of Southeastern Ontario, Kinston General Hospital; and Queen's University, Kingston, ON.
authors.forename: M
authors.initials: M
authors.lastname: Mates
authors.affiliation: Durham Regional Cancer Centre, Oshawa, ON.
authors.forename: O C
authors.initials: OC
authors.lastname: Freedman
authors.affiliation: The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON.
authors.forename: S F
authors.initials: SF
authors.lastname: Dent
authors.affiliation: Sunnybrook Health Science Centre, Toronto, ON.
authors.forename: M E
authors.initials: ME
authors.lastname: Trudeau
keywords: Treatment guidelines; adjuvant systemic treatment; chemotherapy; consensus process; early breast cancer; endocrine therapy; her2-targeted therapy
references.citation: Oncologist. 2012;17(7):900-9
references.pmid: 22610153
references.citation: J Clin Oncol. 2010 Jan 1;28(1):77-82
references.pmid: 19901117
references.citation: Lancet. 2012 Feb 4;379(9814):432-44
references.pmid: 22152853
references.citation: J Natl Cancer Inst. 2012 Jan 18;104(2):159-62
references.pmid: 22138096
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5664-71
references.pmid: 17116941
references.citation: Breast Care (Basel). 2011;6(2):136-141
references.pmid: 21633630
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5685-92
references.pmid: 19884557
references.citation: Lancet. 2013 Mar 9;381(9869):805-16
references.pmid: 23219286
references.citation: Ann Oncol. 2008 Jun;19(6):1090-6
references.pmid: 18296421
references.citation: Lancet Oncol. 2013 Apr;14(4):297-305
references.pmid: 23491275
references.citation: Breast Cancer Res Treat. 2005 Jan;89(1):35-45
references.pmid: 15666195
references.citation: Cancer Control. 2002 Nov-Dec;9(6):466-72
references.pmid: 12514564
references.citation: J Oncol Pract. 2010 Jul;6(4):195-7
references.pmid: 21037871
references.citation: Br J Cancer. 2009 Oct 6;101(7):1074-84
references.pmid: 19724274
references.citation: Lancet Oncol. 2005 Nov;6(11):886-98
references.pmid: 16257797
references.citation: Breast. 2011 Apr;20 Suppl 2:S3-11
references.pmid: 21392996
references.citation: Breast Cancer Res Treat. 2012 Sep;135(2):335-46
references.pmid: 22689092
references.citation: N Engl J Med. 2005 Jun 2;352(22):2302-13
references.pmid: 15930421
references.citation: J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46
references.pmid: 14679153
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2716-25
references.pmid: 15837986
references.citation: BMC Cancer. 2010 May 14;10:205
references.pmid: 20470379
references.citation: J Clin Oncol. 2010 Jan 20;28(3):509-18
references.pmid: 19949017
references.citation: J Clin Oncol. 2006 Jun 1;24(16):2444-7
references.pmid: 16735701
references.citation: J Clin Oncol. 2013 Nov 1;31(31):3997-4013
references.pmid: 24101045
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1168-76
references.pmid: 19204205
references.citation: Arch Pathol Lab Med. 2010 Jun;134(6):907-22
references.pmid: 20524868
references.citation: J Clin Oncol. 1999 Aug;17(8):2365-70
references.pmid: 10561298
references.citation: J Endocrinol. 1976 Sep;70(3):421-8
references.pmid: 978103
references.citation: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references.pmid: 16720680
references.citation: J Clin Oncol. 2011 Feb 20;29(6):651-9
references.pmid: 21245420
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1829-34
references.pmid: 20212256
references.citation: Arch Pathol Lab Med. 2010 Jul;134(7):e48-72
references.pmid: 20586616
references.citation: Ann Oncol. 2012 Oct;23(10):2552-2561
references.pmid: 22431701
references.citation: Arch Pathol Lab Med. 2014 Feb;138(2):241-56
references.pmid: 24099077
references.citation: J Clin Oncol. 1995 Feb;13(2):502-12
references.pmid: 7844612
references.citation: J Clin Oncol. 2009 Jun 20;27(18):2962-9
references.pmid: 19364966
references.citation: N Engl J Med. 2015 Apr 23;372(17):1673
references.pmid: 25901437
references.citation: Ann Oncol. 2000 May;11(5):515-9
references.pmid: 10907942
references.citation: J Clin Oncol. 1998 Mar;16(3):1226-31
references.pmid: 9508211
references.citation: N Engl J Med. 2008 Apr 17;358(16):1663-71
references.pmid: 18420499
references.citation: N Engl J Med. 2009 May 14;360(20):2055-65
references.pmid: 19439741
references.citation: Ann Oncol. 2011 Aug;22(8):1736-47
references.pmid: 21709140
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1177-83
references.pmid: 19204201
references.citation: Jpn J Clin Oncol. 2011 May;41(5):709-12
references.pmid: 21355003
references.citation: J Clin Oncol. 2010 Jul 20;28(21):3422-8
references.pmid: 20530280
references.citation: Lancet Oncol. 2013 Jul;14(8):741-8
references.pmid: 23764181
references.citation: J Clin Oncol. 2014 Dec 10;32(35):3948-58
references.pmid: 25349302
references.citation: Clin Cancer Res. 2010 Aug 1;16(15):3988-97
references.pmid: 20576719
references.citation: Breast. 2011 Apr;20 Suppl 2:S12-9
references.pmid: 21388811
references.citation: Lancet Oncol. 2010 Jan;11(1):55-65
references.pmid: 20005174
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3366-73
references.pmid: 21768458
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1231-8
references.pmid: 18250349
references.citation: Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23
references.pmid: 23970019
references.citation: N Engl J Med. 2005 Oct 27;353(17):1784-92
references.pmid: 16251534
references.citation: J Clin Oncol. 2012 Jan 1;30(1):11-8
references.pmid: 22105826
references.citation: J Clin Oncol. 2010 Oct 1;28(28):4307-15
references.pmid: 20697084
references.citation: J Breast Cancer. 2011 Sep;14(3):198-203
references.pmid: 22031801
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: Clin Breast Cancer. 2012 Oct;12(5):308-12
references.pmid: 23039999
references.citation: J Clin Oncol. 2008 Feb 10;26(5):778-85
references.pmid: 18258986
references.citation: Lancet. 2011 Aug 27;378(9793):771-84
references.pmid: 21802721
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2784-95
references.pmid: 20404251
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: Ann Oncol. 2011 Sep;22(9):2007-2013
references.pmid: 21285132
references.citation: Breast Cancer Res. 2011;13(6):R109
references.pmid: 22044691